Skip to content

Kailera Therapeutics

US · KLRA #3073 by market cap Listed 2026
11.02 -0.56 -4.84%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:30

Price chart

Pre-market 11.21 -3.20%
After-hours 11.23 +1.91%
23.3010.0011.022026-05-262026-11-20
MA5MA10MA20MA60
— MA5 — MA10 — MA20 — MA60
Reader sentiment Are you bullish or bearish on KLRA?

Anonymous reader poll. Unscientific, not investment advice.

✦ StockVane Quant Insights how this is computed

Quant Sentiment Bearish
  • Recent price momentum is -36.9% on average (3-month/1-year).
  • Main-fund capital flow has been a net inflow over the last 45 sessions.
  • Short interest has risen to 6.3% of float.
  • Analyst tilt is Buy.
Quant Technical Outlook Neutral
  • Price is below its 20-day average and below its 60-day average.
  • The 20-day average is above the 60-day average, a short-term uptrend.
Quant Rating, last 30 days C → C

Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.

Performance

1W -16.96%
1M -14.51%
3M -36.88%
6M -45.09%

Key statistics

Price & volume

Prev close
11.58
Open
11.37
Day range
11.00 - 11.87
Avg price
11.23
Volume
553.33K
Turnover
6.21M
Amplitude
7.51%
52-week range
9.76 - 28.23

Valuation

P/E
-1,574.29
P/E (TTM)
-4.89
P/B
1.39
EPS
-0.01
Net profit
-908.95K
Net assets
1.03B

Share structure

Market cap
1.43B
Float cap
644.43M
Shares out
129.85M
Float shares
58.48M

Dividend & listing

Dividend (TTM)
0.00
Listing date
2026-04-17
52-week range 7% of range
9.76 28.23

61.0% below the 52-week high

Trading activity

Net capital flow main funds, last 45 sessions

+8.08M net over the window

Short interest

Shares short
8.16M
As of
2026-10-30

Frequently asked questions

What is the current stock price of Kailera Therapeutics (KLRA)?

Kailera Therapeutics last traded at 11.02. This page shows a periodic quote snapshot. Check the displayed quote time.

What is Kailera Therapeutics's market cap?

About 1.43B.

What is the P/E ratio of Kailera Therapeutics?

The trailing twelve-month P/E is -4.89. The Valuation tab shows it against the stock's own five-year range.

Does Kailera Therapeutics pay a dividend?

Kailera Therapeutics does not currently pay a regular dividend.

Is Kailera Therapeutics a buy according to analysts?

The consensus of 3 analysts is a Buy rating, with an average 12-month price target of 50.50, which implies 358.3% upside from the current price. This is not investment advice.

What is Kailera Therapeutics's StockVane Quant Rating?

The StockVane Momentum strategy currently rates Kailera Therapeutics a C (Hold). Mid-pack momentum — held if you own it, not a fresh buy. Not investment advice.

Quote time 2026-11-20 19:30:06 · For reference only, not investment advice and not tailored to your situation.

Kailera Therapeutics discussion 0 comments

Add a comment